Core Viewpoint - Weight loss is not equivalent to fat loss; the ideal scenario is to reduce fat while preserving muscle mass, as muscle helps maintain basal metabolic rate and body shape [2][4]. Group 1: Weight Loss Mechanism - Over-restrictive dieting can lead to muscle loss primarily due to nutritional deficiencies, as the body prioritizes muscle tissue for energy when caloric intake is significantly low [4]. - Hormonal changes, such as increased cortisol and decreased testosterone levels, can further promote muscle breakdown and inhibit muscle synthesis [4]. - Long-term low-calorie intake may reduce metabolic rate, making it harder to maintain muscle mass [4]. Group 2: GLP-1 Medications - GLP-1 receptor agonists (GLP-1 RAs) mimic the action of the natural hormone GLP-1, which plays a crucial role in blood sugar regulation [5]. - These medications promote insulin secretion in a glucose-dependent manner, helping to lower postprandial blood sugar levels [7]. - GLP-1 RAs inhibit glucagon secretion, which typically raises blood sugar levels when they are low, thus aiding in blood sugar control [7]. - They also delay gastric emptying, reducing the speed at which food enters the small intestine, which helps manage post-meal blood sugar spikes [8]. - Additionally, GLP-1 RAs act on the brain's appetite regulation centers to suppress appetite, aiding in weight management [9]. - Long-term use of GLP-1 RAs may improve or protect pancreatic beta-cell function, which is particularly important for type 2 diabetes patients [10]. Group 3: Weight Loss Results - In the PIONEER PLUS phase 3 study, participants treated with oral semaglutide for 68 weeks lost an average of 9.2 kg (9.54%) and 7.0 kg (7.26%) at doses of 50 mg and 25 mg, respectively [11]. - The latest OASIS 1 study reported that participants in the 50 mg group lost an average of 18.34 kg (17.4%), indicating an improvement in weight loss efficacy [12].

Core Viewpoint - A new study published in the Annals of Internal Medicine emphasizes the need for a revised Body Mass Index (BMI) standard for Asian populations due to unique obesity characteristics that increase health risks even at lower BMI levels [4][5]. Group 1: Research Findings - The research led by Dr. Simar S. Bajaj indicates that Asians are prone to central obesity, which poses higher health risks such as type 2 diabetes and cardiovascular diseases, even with a lower BMI [5]. - The study advocates for the establishment of specific BMI thresholds for Asian populations, highlighting the necessity for further research to determine exact values [5]. - Current global obesity diagnostic standards may undergo significant changes based on these findings, as the study suggests that existing standards do not adequately reflect the health risks faced by Asians [5]. Group 2: Current Standards and Discrepancies - The World Health Organization (WHO) has not set a unified standard for obesity in Asia, allowing countries to adjust their standards based on local health risks, leading to significant discrepancies among countries like India and China [7]. - In the United States, there is ongoing debate regarding the classification of Asian populations under a single BMI standard, with some organizations proposing adjustments to the BMI thresholds for Asian individuals [8][9]. - The American Diabetes Association (ADA) and the American Society for Metabolic and Bariatric Surgery (ASMBS) have suggested lowering the BMI screening thresholds for Asians to 23 kg/m² and 27.5 kg/m² respectively [9]. Group 3: Implications for Future Research - Recent studies indicate that different Asian ethnic groups exhibit varying diabetes risk levels at the same BMI, challenging the notion of a homogeneous Asian population regarding obesity risk [11]. - A large-scale study involving 147,000 participants confirmed that the BMI threshold for diabetes risk differs significantly among ethnic groups, necessitating a more nuanced approach to obesity standards [11]. - The research highlights the importance of incorporating additional metrics such as waist circumference and waist-to-hip ratio, especially for populations with a BMI of 23 or higher, to enhance the precision of obesity assessments [11].

Core Viewpoint - The article discusses a groundbreaking study revealing a new physiological phenomenon where the central nervous system regulates intestinal nutrient absorption, particularly fat, through the vagus nerve, with implications for obesity and metabolic disease treatment [10]. Group 1: Research Findings - The study identifies that the Phox2b neurons in the dorsal motor nucleus of the vagus (DMV) can significantly influence fat absorption in the intestines, leading to weight loss in mice on a high-fat diet [7]. - The research team discovered that the herbal compound puerarin can reduce the activity of Phox2b DMV neurons, promoting fat excretion and aiding weight loss [8]. - The study confirmed that the GABRA1 protein, a subunit of the GABA A receptor, is a key target for puerarin, which enhances chloride ion influx and inhibits DMV neuron activity [9]. Group 2: Mechanism of Action - The research demonstrated that the inhibition of DMV neurons or intervention with puerarin leads to a significant reduction in the length of intestinal microvilli, which is crucial for fat absorption [9]. - The study utilized advanced techniques such as pharmacogenetics, neurophysiology, and structural biology to elucidate the molecular mechanisms by which puerarin exerts its effects [10]. Group 3: Implications for Future Research - The findings open new avenues for drug development targeting obesity and metabolic diseases by modulating the central regulation of intestinal fat absorption [10]. - The research highlights the potential for further exploration of the brain-gut signaling pathways, which could lead to innovative therapeutic strategies for managing obesity [10].

Core Viewpoint - The article discusses the promising results of the oral small molecule GLP-1 receptor agonist MDR-001 developed by Derui Zhiya, which shows significant weight loss in overweight or obese individuals after a 12-week treatment period [2][3]. Group 1: Study Results - The study included 24 adult participants, randomly assigned in a 2:1 ratio to receive either MDR-001 or a placebo for 12 weeks [3]. - The MDR-001 group experienced an average weight loss of 8.9%, compared to 0.6% in the placebo group, resulting in a net weight loss of 8.3% after adjusting for placebo effects [2][3]. - 93.8% of participants in the MDR-001 group achieved at least a 5% weight loss, and 37.5% achieved at least a 10% weight loss, with beneficial changes observed in various metabolic and cardiovascular indicators [3]. Group 2: Safety and Tolerability - The overall safety and tolerability of MDR-001 were reported to be good, with no serious adverse events noted during the trial [3]. - The most common side effects were gastrointestinal reactions, which were mostly mild to moderate and manageable [3]. Group 3: Comparison with Previous Studies - The article highlights that in a previous Phase IIb study using a "twice daily" (BID) dosing regimen, a weight loss of 10.3% was reported over 24 weeks, indicating that the current "once daily" (QD) regimen provides new evidence for dosing frequency optimization and long-term validation [3].

Core Insights - The article discusses the significant impact of GLP-1 receptor agonists (GLP-1RAs) on obesity management, highlighting the challenge of weight rebound after discontinuation of medication [2] - A Danish randomized controlled trial indicates that incorporating supervised exercise during the treatment and withdrawal phases can significantly improve weight and body composition maintenance after one year [2] Research Design and Methodology - The trial included obese adults aged 18-65 with a BMI of 32-43 kg/m², progressing through three phases: - Induction phase (8 weeks): Strict low-calorie diet (~800 kcal/day), average weight loss of approximately 13.1 kg - Randomized maintenance phase (52 weeks): Participants were assigned to supervised exercise, liraglutide 3.0 mg/day, a combination of both, or a placebo - Follow-up phase (52-104 weeks): All interventions ceased at week 52, with assessments at week 104 for weight and body fat changes - The primary endpoint was weight change from randomization (week 0) to one year post-discontinuation (week 104), with secondary endpoints including percentage change in body fat [3] Key Findings and Evidence - The combination of supervised exercise and liraglutide showed a persistent advantage: one year post-discontinuation, the combination group had a lower weight (approximately -5.1 kg, statistically significant) and a significant decrease in body fat percentage (approximately -2.3 percentage points) compared to liraglutide alone [5] - Weight regain was more pronounced in the liraglutide-only group (approximately +6.0 kg) compared to the supervised exercise group (approximately +3.6 kg), indicating better stability in the exercise group [5] Body Composition and Functional Benefits - The combination group exhibited clearer reductions in body fat and waist circumference, with lean body mass increasing across all groups - Quality of life metrics indicated that the combination group outperformed the liraglutide-only group in energy/fatigue and physical function, while the supervised exercise group also showed improvements in energy/fatigue and pain [7] Mechanisms and Practical Implications - During the weight loss induction phase, the medication suppresses appetite and reduces intake, but after discontinuation, energy intake and appetite signals may revert to previous levels, leading to weight regain - Supervised exercise can enhance insulin sensitivity, increase resting energy expenditure, preserve lean body mass, and improve appetite regulation and psychological state, helping to establish a new energy balance during the withdrawal phase - Previous observations indicated that approximately 67% of weight loss achieved with semaglutide is regained after discontinuation, supporting the complementary relationship between medication and exercise [10] Conclusion - Obesity is a chronic and relapsing condition; while medications can effectively reduce weight, the long-term outcome depends on the ability to maintain exercise and lifestyle changes post-medication - Viewing supervised exercise as a long-term prescription, alongside medication and intensified during the withdrawal phase, is currently one of the most evidence-supported and feasible strategies [10]

Core Viewpoint - The article discusses the recent announcement by Borui Pharmaceutical regarding its plan to issue H-shares and list on the Hong Kong Stock Exchange, while emphasizing the company's commitment to balancing shareholder interests with market conditions [2]. Product Portfolio - Borui Pharmaceutical has a diverse product line covering multiple therapeutic areas, including metabolism, antiviral, antifungal, immunosuppressive, respiratory, and oncology. Key innovative drugs in the metabolism category include BGM0504 and BGM1812, while antiviral products include Entecavir and Oseltamivir. The antifungal category features Caspofungin and Micafungin Sodium, among others [3]. Financial Performance and R&D Progress - In the first half of 2025, Borui Pharmaceutical reported a revenue of 537 million yuan and a net profit of 14.36 million yuan after deducting non-recurring items. The company is focusing on multi-target metabolic drugs containing GLP-1 and exploring new administration routes beyond injections for chronic metabolic diseases. The self-developed peptide-based hypoglycemic drug BGM0504, a dual receptor agonist for GLP-1 and GIP, shows potential in controlling blood sugar, weight loss, and treating non-alcoholic fatty liver disease (NASH). Currently, BGM0504 has completed patient enrollment for phase III clinical trials in China for both type 2 diabetes and weight loss indications, with progress being reported as smooth [5]. Industry Engagement - The "GLP-1 Club" has established a network of hundreds of professionals, providing a platform for industry insights and discussions related to the GLP-1 drug development and its applications in weight loss and diabetes management [9]. GLP-1 Drug Overview - GLP-1 (Glucagon-like peptide-1) is a hormone produced by intestinal L cells, classified as an incretin. GLP-1 receptor agonists are a new class of hypoglycemic drugs that enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, leading to reduced food intake and lower blood sugar levels [13].

Core Viewpoint - The article discusses a recent study published in *Nature Metabolism* by a team from Shanghai Jiao Tong University, which demonstrates that resistant starch (RS) can significantly aid overweight or obese individuals in weight loss and improving metabolic health through modulation of gut microbiota and metabolic pathways [6][8]. Group 1: Research Highlights - The study integrates microbiome and metabolomics data to comprehensively assess the impact of resistant starch on gut microbiota structure and human metabolism [6]. - It employs a randomized, placebo-controlled crossover trial design, enhancing the reliability of results by minimizing confounding variables [6]. - The research reveals that resistant starch affects bile acid metabolism, reduces inflammation, repairs gut barriers, and inhibits lipid absorption, providing a new theoretical basis for obesity prevention and treatment [6][8]. Group 2: Study Methodology - The study included participants aged 18 to 55 years, classified as overweight or obese (BMI ≥ 24 kg/m²), and excluded those with acute diseases or recent antibiotic use [9]. - A randomized controlled crossover design was used to evaluate the effects of resistant starch on weight control and insulin resistance, combined with metagenomic and metabolomic techniques to analyze gut microbiota changes [10]. Group 3: Key Findings - The intervention with resistant starch resulted in significant weight loss, reduced fat mass, and improved insulin sensitivity among 37 overweight or obese participants over an 8-week period [11]. - Resistant starch increased the abundance of beneficial bacteria such as *Bifidobacterium*, enhancing gut barrier function and reducing inflammation [11][13]. - In animal models, the transplantation of gut microbiota from resistant starch-fed humans led to lower body weight and fat mass, indicating the effectiveness of RS-modulated gut microbiota in weight management [16]. Group 4: Mechanisms of Action - The study found that resistant starch-induced gut microbiota changes lowered systemic inflammation markers and improved gut barrier integrity, which is crucial for managing obesity-related chronic inflammation [18][19]. - The increase in *Bifidobacterium adolescentis* was closely linked to the alleviation of abdominal obesity, suggesting its potential role in metabolic health [21].

Core Viewpoint - The article emphasizes the critical role of managing prediabetes and obesity in preventing the progression to diabetes and cardiovascular diseases, highlighting the effectiveness of the drug Semaglutide (weight loss version) in improving health outcomes for overweight and prediabetic patients [5][6][20]. Group 1: Prediabetes and Health Risks - Prediabetes is a significant health warning signal, with 5%-10% of patients progressing to diabetes annually, and it is associated with increased cardiovascular risks [5][8]. - Meta-analysis shows that prediabetic patients have higher all-cause mortality and cardiovascular event rates compared to those with normal blood sugar levels [8][26]. Group 2: Obesity as a Risk Factor - There is a strong positive correlation between obesity and the risk of prediabetes, with risk increasing significantly as BMI rises: 25% increase for BMI 25.0-29.9 kg/m² and 184% for BMI ≥40 kg/m² [9][11]. - The 2023 Expert Consensus on Diabetes Prediabetes Intervention emphasizes weight management as a core strategy to prevent the progression of prediabetes [9][11]. Group 3: Semaglutide's Impact - The SELECT study demonstrated that Semaglutide (weight loss version) significantly reduces the risk of major cardiovascular adverse events (MACE) by 20% compared to placebo [17][18]. - The drug also shows remarkable effects on blood sugar control, with nearly 70% of patients achieving normal blood sugar levels, far exceeding the placebo group [18][20]. Group 4: Future Outlook - There is optimism that more prediabetic patients will receive early intervention, leading to improved long-term outcomes for overweight and obese individuals [21][22]. - The treatment of metabolic diseases is expected to enter a new era of precision and individualization [22].

Core Viewpoint - The article emphasizes the importance of adequate protein intake while using semaglutide, a GLP-1 receptor agonist, for weight loss and overall health maintenance [2][5]. Group 1: Importance of Protein Intake - Sufficient protein intake is crucial during semaglutide treatment to maintain muscle mass [2][4]. - A balanced diet including protein, vegetables, and whole grains is recommended to enhance fiber intake and reduce side effects like constipation [2][5]. Group 2: Mechanism of GLP-1 Drugs - GLP-1 receptor agonists promote insulin secretion by activating GLP-1 receptors on pancreatic beta cells, which is glucose-dependent [6]. - They inhibit glucagon secretion from pancreatic alpha cells, helping to lower blood sugar levels [6]. - GLP-1 drugs delay gastric emptying, controlling postprandial blood sugar spikes [7]. - They also regulate appetite by acting on the brain's appetite centers, aiding in food intake reduction and weight management [8]. Group 3: Metabolic Effects - Research indicates that GLP-1 drugs not only increase satiety but also directly influence metabolism [10]. - Individuals using GLP-1 analogs exhibit increased metabolic activity, leading to higher energy expenditure and potential weight loss [11][13].

Core Viewpoint - The research team from East China Normal University has made significant advancements in the field of obesity and metabolic diseases, discovering that beige fat can be activated through local thermal therapy to alleviate obesity and improve metabolic disorders. This finding was published in the prestigious journal "Cell" and selected as a cover article [6][9]. Group 1: Research Findings - The study reveals that beige fat, which has characteristics of both white and brown fat, can be activated by local heat therapy, leading to increased thermogenesis and energy expenditure [7][10]. - The research identified the heat shock transcription factor 1 (HSF1) as a key player in sensing local heat and activating thermogenic mechanisms, which can effectively combat obesity and improve insulin resistance and liver lipid accumulation [9][12]. - A large-scale clinical study established a correlation between HSF1 and various metabolic traits, providing new targets and strategies for obesity intervention [9][14]. Group 2: Implications and Applications - The findings suggest that local thermal therapy could be a safe and effective method for weight loss, without affecting the sympathetic or immune systems, indicating its potential as a new direction for obesity treatment [9][12]. - Traditional thermal therapies, such as those used in Chinese medicine, have been recognized for their metabolic benefits, but the study emphasizes the need for safer and more effective activation methods for beige fat [10][12]. - The research lays a solid foundation for the development of new clinical drugs and precision treatments targeting metabolic disorders [14].